MAPT and Alzheimer disease: Some GSK-3 targets are of particular relevance to AD, including Aβ peptide and tau protein, the components of the main pathological hallmarks of AD, namely neuritic plaques (NPs) and neurofibrillary tangles (NFTs), respectively [5,59,60]